Pacific Biosciences of California, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Pacific Biosciences of California, Inc. (PACB) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$546.38 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-02-25
- Pacific Biosciences of California, Inc. net income (loss) available to common stockholders, diluted for fiscal 2025 was -$546.38M.
- Pacific Biosciences of California, Inc. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$457.83M.
- Pacific Biosciences of California, Inc. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$306.74M.
- Pacific Biosciences of California, Inc. net income (loss) available to common stockholders, diluted for fiscal 2022 was -$314.25M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|
| 2025-12-31 | -$546.38M 10-K · filed 2026-02-25 |
| 2024-12-31 | -$457.83M 10-K · filed 2026-02-25 |
| 2023-12-31 | -$306.74M 10-K · filed 2026-02-25 |
| 2022-12-31 | -$314.25M 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |